Skip to Main Content

Biogen Inc. (NASDAQ: BIIB) Securities Fraud Class Action

View Complaint
COMPANY       Biogen Inc. 
COURT United States District Court for the District of Colorado
CASE NUMBER 24-cv-01444
JUDGE The Hon. Philip A. Brimmer
CLASS PERIOD  February 3, 2022 through February 13, 2024
SECURITY TYPE  Securities

Case Background:

This is a class action lawsuit on behalf of those who purchased or acquired Biogen Inc. (“Biogen”) (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024, both dates inclusive (the “Class Period”). 

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Biogen had overstated its efforts to enhance its transparency, corporate governance, and compliance controls and procedures, as well as the efficacy of those controls and procedures; (2) accordingly, Biogen maintained inadequate compliance controls and procedures in connection with its business operations in foreign countries; (3) Biogen and/or its employees were engaged in unlawful or otherwise improper conduct in several foreign countries; (4) the foregoing subjected the Company to a heightened risk of governmental and/or regulatory scrutiny and enforcement action, as well as significant legal, financial, and reputational harm; (5) Biogen overstated the strength of its AD-related product portfolio, including the Company's and Eisai's efforts and success in launching and providing access to Leqembi; (6) Biogen also downplayed the negative impact that the Reata Acquisition would have on its FY 2023 non-GAAP diluted EPS; (7) all the foregoing were likely to have a significant negative impact on Biogen's 2023 results; and (8) as a result, the Company's public statements were materially false and misleading at all relevant times.

Current Status of Case:

On, May 22, 2024, the Initial Complaint was filed. A Motion for Appointment as Lead Plaintiff and Approval of Lead Counsel was filed July 22, 2024. The Motion to Appoint Lead Plaintiff and Approve Lead Counsel is pending before the Court.  This action is ongoing. 

If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at info@ktmc.com.

Complete this form with your transactions in Biogen Inc. securities between February 3, 2022 and February 13, 2024

Click Here to Print PDF of this Form

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Biogen Inc. (2024) prior to the Class Period?
Are you a current or former employee of Biogen Inc. (2024)?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email